Advanced Enzyme Technologies Limited

rs,

September 22, 2025 BSE Limited P. J. Towers, Dalal Street, Mumbai- 400 001 National Stock Exchange of India Limited Exchange Plaza, Plot No.

3%

harashtra Andhra Pradesh GERMANY North Rhine-Westfalia USA California 6 1 1 1 4 1 1 1 3% 9% 46% FY25 5% 37% Investors Presentation | September’25 9 India USA Europe Asia Rest of

9%

shtra Andhra Pradesh GERMANY North Rhine-Westfalia USA California 6 1 1 1 4 1 1 1 3% 9% 46% FY25 5% 37% Investors Presentation | September’25 9 India USA Europe Asia Rest of the

46%

a Andhra Pradesh GERMANY North Rhine-Westfalia USA California 6 1 1 1 4 1 1 1 3% 9% 46% FY25 5% 37% Investors Presentation | September’25 9 India USA Europe Asia Rest of the Worl

5%

radesh GERMANY North Rhine-Westfalia USA California 6 1 1 1 4 1 1 1 3% 9% 46% FY25 5% 37% Investors Presentation | September’25 9 India USA Europe Asia Rest of the World Caterin

37%

sh GERMANY North Rhine-Westfalia USA California 6 1 1 1 4 1 1 1 3% 9% 46% FY25 5% 37% Investors Presentation | September’25 9 India USA Europe Asia Rest of the World Catering to

64%

eptember’25 9 India USA Europe Asia Rest of the World Catering to Diverse end-use Industries 64% Human Healthcare & Nutrition 12% Animal Healthcare & Nutrition 13% Bio Processing Food 03%

12%

Asia Rest of the World Catering to Diverse end-use Industries 64% Human Healthcare & Nutrition 12% Animal Healthcare & Nutrition 13% Bio Processing Food 03% Bio Processing Non - Food 08% Sp

13%

Diverse end-use Industries 64% Human Healthcare & Nutrition 12% Animal Healthcare & Nutrition 13% Bio Processing Food 03% Bio Processing Non - Food 08% Specialized Manufacturing 24% - Phar

03%

64% Human Healthcare & Nutrition 12% Animal Healthcare & Nutrition 13% Bio Processing Food 03% Bio Processing Non - Food 08% Specialized Manufacturing 24% - Pharmaceuticals Poultry feed

08%

on 12% Animal Healthcare & Nutrition 13% Bio Processing Food 03% Bio Processing Non - Food 08% Specialized Manufacturing 24% - Pharmaceuticals Poultry feed Baking Yeast Processing Textile

24%

ition 13% Bio Processing Food 03% Bio Processing Non - Food 08% Specialized Manufacturing 24% - Pharmaceuticals Poultry feed Baking Yeast Processing Textile Processing Effervescent Tablets

Ref

1

Note

1

Notes

1

Investor Relations Contact

1

Ref

Investor Presentation ISIN: INE837H01020 Dear Sir/Madam, Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation to our intimation dated September 19, 2025, enclosed is the Investor Presentation for the Pharma and Healthcare conference – by DAM Capital Advisors Limited, to be held on September 23, 2025. This is for your information and for public at large. Thanking you, Yours faithfully, For Advanced Enzyme Technologies Limited Sanjay Basantani Company Secretary and Head – Legal Encl.: As above Advanced Enzyme Technologies Limited Investors Presentation | September 2025 Safe Harbour Statement This presentation contains forward-looking statements that reflect management’s current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words “believe,” “expect,” “anticipate,” “inten

Note

1. 2. 3. Investors Presentation | September’25 23 Strong Financial Performance – FY25 Net Working Capital (Days) 120 132 135 135 146 Net Worth (₹ mn) 12,351 13,241 14,209 9,709 10,886 FY 21 FY 22 FY23 FY 24 FY 25 FY 21 FY 22 FY 23 FY 24 FY 25 ROE (%) & ROCE (%) Net Debt to Equity (x) 21.94% 16.71% 15.93% 12.02% 10.34% 8.94% 13.03% 10.71% 11.31% 9.76% FY 21 FY 22 FY 23 FY 24 FY 25 ROE (%) ROCE (%) ROIC (%) 0.02 0.02 0.02 0.01 0.01 FY 21 FY 22 FY 23 FY 24 FY 25 Note: All the numbers are as per IndAs All numbers are on Consolidated basis Net working capital days =((Trade receivables + inventories – Trade payables)/ Revenue from operations)*365 Net Debt = Long term debt + short term debt + current maturities of long term debt – Cash & Cash Equivalent ROE = Profit after tax / Average shareholder equity; RoCE = (Net Profit before Tax , Exceptional and extraordinary items + Finance cost) / Average (Net debt + Networth) Investors Presentation | September’25 24 Results Summary – Q1 FY26 (Consol

Notes

1. All the decimals are rounded off to their relevant nearest number Investors Presentation | September’25 26 Future Growth Strategies & Pipeline Investors Presentation | September’25 27 Key Strategies for Future Growth o Increased focus on high return applications where AETL has strategic advantages o Build Strategic Partnerships in Key Markets for Focus Segments Continued Investment in R&D Inorganic Expansion Broaden & Deepen Geographical Presence o Identify Product gaps and Develop new Enzymes, Probiotics & Solutions thereof o Expand Competencies in Enzymes & Probiotics, Discovery and Genetic Engineering o Acquisition of Key Technologies, Competencies & Skill-sets which Enable Consolidation and/or Entry into New Market Segments o Acquisition of Client Relationships & Businesses in Key Focus Markets Investors Presentation | September’25 28 Focus Areas Going Ahead Animal Nutrition Probiotics Bio-Catalysis Baking Continuing conduct trials and studies to bring newer and effective nutrit